First prescription (days before first MI)* | Cases (n = 63512) | Controls (n = 378886) | OR (95% CI) |
---|---|---|---|
*Baseline group has no prescriptions before first MI; †0 days is the day of first MI. | |||
SSRIs | |||
Any SSRI | |||
0† | 13 (0.02%) | 16 (0%) | 4.96 (2.39 to 10.32) |
1–7 | 37 (0.06%) | 84 (0.02%) | 2.66 (1.81 to 3.92) |
8–14 | 25 (0.04%) | 83 (0.02%) | 1.79 (1.15 to 2.81) |
15–21 | 24 (0.04%) | 79 (0.02%) | 1.86 (1.18 to 2.95) |
22–28 | 22 (0.03%) | 80 (0.02%) | 1.65 (1.03 to 2.65) |
>28 | 2428 (3.82%) | 10097 (2.66%) | 1.47 (1.41 to 1.54) |
Fluoxetine | |||
0† | 10 (0.02%) | 4 (0%) | 15.09 (4.73 to 48.11) |
1–7 | 16 (0.03%) | 37 (0.01%) | 2.59 (1.44 to 4.66) |
8–14 | 14 (0.02%) | 43 (0.01%) | 1.89 (1.03 to 3.48) |
15–21 | 12 (0.02%) | 35 (0.01%) | 2.08 (1.08 to 4.01) |
22–28 | 12 (0.02%) | 44 (0.01%) | 1.65 (0.87 to 3.12) |
>28 | 1263 (1.99%) | 5062 (1.34%) | 1.51 (1.42 to 1.61) |
Paroxetine | |||
0† | 3 (0%) | 8 (0%) | 2.29 (0.61 to 8.64) |
1–7 | 18 (0.03%) | 34 (0.01%) | 3.18 (1.80 to 5.63) |
8–14 | 11 (0.02%) | 26 (0.01%) | 2.56 (1.26 to 5.18) |
15–21 | 11 (0.02%) | 34 (0.01%) | 1.95 (0.99 to 3.85) |
22–28 | 11 (0.02%) | 31 (0.01%) | 2.12 (1.06 to 4.21) |
>28 | 816 (1.28%) | 3706 (0.98%) | 1.33 (1.23 to 1.43) |
TCAs | |||
Any TCA | |||
0† | 9 (0.01%) | 25 (0.01%) | 2.28 (1.06 to 4.88) |
1–7 | 50 (0.08%) | 148 (0.04%) | 2.07 (1.50 to 2.86) |
8–14 | 49 (0.08%) | 152 (0.04%) | 2.02 (1.46 to 2.78) |
15–21 | 62 (0.1%) | 170 (0.04%) | 2.24 (1.68 to 3.01) |
22–28 | 48 (0.08%) | 157 (0.04%) | 1.89 (1.37 to 2.62) |
>28 | 7369 (11.6%) | 33074 (8.73%) | 1.40 (1.36 to 1.43) |
Dothiepin | |||
0† | 4 (0.01%) | 12 (0%) | 2.05 (0.66 to 6.37) |
1–7 | 20 (0.03%) | 64 (0.02%) | 1.90 (1.15 to 3.14) |
8–14 | 21 (0.03%) | 68 (0.02%) | 1.88 (1.15 to 3.07) |
15–21 | 22 (0.03%) | 76 (0.02%) | 1.77 (1.10 to 2.84) |
22–28 | 16 (0.03%) | 69 (0.02%) | 1.42 (0.83 to 2.46) |
>28 | 2843 (4.48%) | 13142 (3.47%) | 1.32 (1.26 to 1.38) |
Amitriptyline | |||
0† | 0 (0%) | 11 (0%) | |
1–7 | 25 (0.04%) | 59 (0.02%) | 2.53 (1.58 to 4.05) |
8–14 | 22 (0.03%) | 70 (0.02%) | 1.92 (1.19 to 3.11) |
15–21 | 23 (0.04%) | 55 (0.01%) | 2.42 (1.48 to 3.95) |
22–28 | 14 (0.02%) | 69 (0.02%) | 1.23 (0.69 to 2.19) |
>28 | 2543 (4.0%) | 11236 (2.97%) | 1.38 (1.32 to 1.44) |
Lofepramine | |||
0† | 6 (0.01%) | 5 (0%) | 7.25 (2.21 to 23.75) |
1–7 | 12 (0.02%) | 29 (0.01%) | 2.52 (1.29 to 4.94) |
8–14 | 12 (0.02%) | 29 (0.01%) | 2.53 (1.29 to 4.96) |
15–21 | 19 (0.03%) | 39 (0.01%) | 2.97 (1.71 to 5.13) |
22–28 | 14 (0.02%) | 27 (0.01%) | 3.02 (1.57 to 5.79) |
>28 | 1331 (2.1%) | 5518 (1.46%) | 1.46 (1.37 to 1.55) |